IGF-1 can appear prominently in discussions of growth-hormone-related care. When a provider points to a laboratory change, it is reasonable to ask what that change means for the clinical question. A number can be informative without proving every benefit suggested by an advertisement.
This guide helps organize that conversation. It does not supply a target IGF-1 value, diagnose a deficiency, interpret your personal result, or recommend a dose. Those decisions require the clinical context and the actual laboratory information.
This guide helps organize that conversation. It does not supply a target IGF-1 value, diagnose a deficiency, interpret your personal result, or recommend a dose. Those decisions require the clinical context and the actual laboratory information.
Begin with the reason for testing
Ask what question the clinician wants the test to answer. Is it part of evaluating a suspected condition, establishing a baseline, or monitoring an existing treatment? Those purposes are related but not identical. A result should be interpreted for the question it was ordered to address.
The Endocrine Society guideline on adult growth hormone deficiency describes a diagnostic process that usually involves stimulation testing, with specified exceptions. It does not support diagnosing everyone from a symptom list or a single online score. Bring prior results and relevant history to the clinician rather than comparing your number with strangers' posts.
Write down the outcome you care about
A person may care about functioning during the day, a persistent symptom, or a diagnosed condition. Ask the clinician how that concern will be evaluated and what would count as a worthwhile improvement. This creates a separate question from whether a laboratory marker changes.
The Endocrine Society statement on hormones and aging distinguishes aging-related changes from endocrine disease. Our benefits and evidence guide puts that distinction alongside common sermorelin claims. Age alone does not settle the explanation for a new concern.
Ask how the two are connected
If a provider says a marker predicts a benefit, request the supporting evidence and ask whether it studied the same population, treatment, and outcome. “This measurement changed” is a narrower statement than “this treatment improved the concern that brought you here.” Both statements need their own support.
Our study-reading checklist helps you identify what was actually measured. If only a laboratory outcome was reported, do not silently replace it with a claim about better sleep, improved mobility, or longer life. A proposed connection should be described as a proposed connection until the relevant evidence is available.
Plan the conversation before the next result
Ask when reassessment will happen, which information will be reviewed, and what circumstances would prompt an earlier call. Report symptoms and adverse effects even when a laboratory value seems reassuring. A monitoring plan should be explained by the treating clinician and tied to the prescribed preparation.
Do not change treatment to chase a number from a forum or provider advertisement. Our safety guide and consultation checklist can help you prepare the questions, but neither can interpret an individual result.
Keep the service decision separate
A provider's price, communication options, pharmacy arrangements, and renewal policy remain useful purchasing information. They are not proof that its program will deliver a particular laboratory or health outcome. Read the CoreAge Rx review or browse the provider index with that separation in mind.
Keep a short record of the question, the clinician's explanation, the result, and the agreed next step. The purpose is continuity of care and clearer discussion, not self-directed hormone management.
The source notes
Sources & further reading
Provider pages document advertised offers, not independently proven outcomes. Historical references may concern different products or uses. Sources were checked for this edition on September 21, 2026; offers can change.